Comparative Pharmacology
Head-to-head clinical analysis: CONZIP versus DURADYNE DHC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONZIP versus DURADYNE DHC.
CONZIP vs DURADYNE DHC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Category C
Category C
Opioid Analgesic
Opioid Analgesic